Cohen Fred E
SEC insider (Form 3/4/5 filer). CIK 0001339358. Director at CareDx, Inc. (CDNA) and 2 other issuers. 7 reported Form 4/5 transactions since Sep 2024; latest on Jun 12, 2026. Located in CAMBRIDGE, MA.
Companies Cohen Fred E has filed insider reports for
- CareDx, Inc. (CDNA): Director
- Intellia Therapeutics, Inc. (NTLA): Director
- Kyverna Therapeutics, Inc. (KYTX): Director
Cohen Fred E
CIK: 0001339358
Transaction Breakdown
Open Market Buys (P)1 (14.3%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)6 (85.7%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (7 total)
- Jun 12, 2026CDNA
CareDx, Inc.
AwardDirect9.8K shares- - Jun 9, 2026NTLA
Intellia Therapeutics, Inc.
AwardDirect9.2K shares- - May 27, 2026KYTX
Kyverna Therapeutics, Inc.
AwardDirect5.1K shares- - Jan 5, 2026NTLA
Intellia Therapeutics, Inc.
PurchaseDirect150K shares at avg. $9.35$1.4M - Jun 13, 2025CDNA
CareDx, Inc.
AwardDirect12.1K shares- - Jun 11, 2025NTLA
Intellia Therapeutics, Inc.
AwardDirect8K shares- - May 29, 2025KYTX
Kyverna Therapeutics, Inc.
AwardDirect16.6K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 12, 2026 |  CDNA CareDx, Inc. | Award | 9,795 | - | $0 | Direct |
| Jun 9, 2026 |  NTLA Intellia Therapeutics, Inc. | Award | 9,200 | - | $0 | Direct |
| May 27, 2026 |  KYTX Kyverna Therapeutics, Inc. | Award | 5,093 | - | $0 | Direct |
| Jan 5, 2026 | NTLA Intellia Therapeutics, Inc. | Purchase | 150,000 | $9.35 | $1,402,500 | Direct |
| Jun 13, 2025 | CDNA CareDx, Inc. | Award | 12,103 | - | - | Direct |
| Jun 11, 2025 | NTLA Intellia Therapeutics, Inc. | Award | 8,000 | - | - | Direct |
| May 29, 2025 | KYTX Kyverna Therapeutics, Inc. | Award | 16,634 | - | - | Direct |
1-7 of 7 transactions